Automating bioinformatics workflows and data

PipeBio is revolutionizing drug development by offering a no-code, cloud-based SaaS bioinformatics platform that accelerates the creation of therapeutics 10x faster. Their platform integrates configurable sequence and assay-data databases with a robust analytical engine for large NGS datasets, REST API, and intuitive visualization tools. Designed to structure data for machine learning and AI applications, PipeBio empowers the scientific community to optimize the development of antibodies and antibody-like therapeutics. PipeBio was acquired by Benchling in 2024.

‍